{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:20:19Z","timestamp":1790774419610,"version":"4.1.0"},"reference-count":253,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1124\/dmd.122.001011","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T15:45:14Z","timestamp":1681227914000},"page":"936-949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets"],"prefix":"10.1016","volume":"51","author":[{"given":"Robert S.","family":"Foti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.122.001011_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4155\/fmc-2017-0137","article-title":"Synthesis and molecular modeling of new benzimidazoles as glutathione S-transferase inhibitors and anticancer agents","volume":"10","author":"Abd El-Karim","year":"2018","journal-title":"Future Med Chem"},{"key":"10.1124\/dmd.122.001011_bib2","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/emboj\/18.5.1321","article-title":"Regulation of JNK signaling by GSTp","volume":"18","author":"Adler","year":"1999","journal-title":"EMBO J"},{"key":"10.1124\/dmd.122.001011_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.0022-202X.2004.23307.x","article-title":"Cytochrome P450: a target for drug development for skin diseases","volume":"123","author":"Ahmad","year":"2004","journal-title":"J Invest Dermatol"},{"key":"10.1124\/dmd.122.001011_bib4","doi-asserted-by":"crossref","first-page":"9469","DOI":"10.1021\/jo801053u","article-title":"Studies on the mechanism of aldehyde oxidase and xanthine oxidase","volume":"73","author":"Alfaro","year":"2008","journal-title":"J Org Chem"},{"key":"10.1124\/dmd.122.001011_bib5","doi-asserted-by":"crossref","first-page":"12433","DOI":"10.3390\/ijms232012433","article-title":"Cardiac disease alters myocardial tissue levels of epoxyeicosatrienoic acids and key proteins involved in their biosynthesis and degradation","volume":"23","author":"Aliwarga","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.001011_bib6","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3389\/fonc.2019.00606","article-title":"Inactivation of prostaglandin E2 as a mechanism for UGT2B17-mediated adverse effects in chronic lymphocytic leukemia","volume":"9","author":"Allain","year":"2019","journal-title":"Front Oncol"},{"key":"10.1124\/dmd.122.001011_bib7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41416-019-0722-0","article-title":"Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression","volume":"122","author":"Allain","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.122.001011_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41416-020-0887-6","article-title":"UGT2B17 modifies drug response in chronic lymphocytic leukaemia","volume":"123","author":"Allain","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1124\/dmd.122.001011_bib9","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41389-017-0025-3","article-title":"Glutathione transferases: substrates, inhibitors and pro-drugs in cancer and neurodegenerative diseases","volume":"7","author":"Allocati","year":"2018","journal-title":"Oncogenesis"},{"key":"10.1124\/dmd.122.001011_bib10","doi-asserted-by":"crossref","first-page":"5581","DOI":"10.1038\/s41598-021-85188-4","article-title":"Profiling of CYP4Z1 and CYP1B1 expression in bladder cancers","volume":"11","author":"Al-Saraireh","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.001011_bib11","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.7150\/jca.42669","article-title":"CYP1B1 gene: Implications in glaucoma and cancer","volume":"11","author":"Alsubait","year":"2020","journal-title":"J Cancer"},{"key":"10.1124\/dmd.122.001011_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3028387","article-title":"The multifarious link between cytochrome P450s and cancer","volume":"2020","author":"Alzahrani","year":"2020","journal-title":"Oxid Med Cell Longev"},{"key":"10.1124\/dmd.122.001011_bib13","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jcph.1545","article-title":"Concept of pharmacologic target-mediated drug disposition in large-molecule and small-molecule compounds","volume":"60","author":"An","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib14","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/jcph.1763","article-title":"Target-mediated drug disposition-A class effect of soluble epoxide hydrolase inhibitors","volume":"61","author":"An","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1002\/jcph.531","article-title":"Small-molecule compounds exhibiting target-mediated drug disposition - a case example of ABT-384","volume":"55","author":"An","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2407-9-187","article-title":"Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention","volume":"9","author":"Androutsopoulos","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1124\/dmd.122.001011_bib17","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1021\/acs.biochem.7b01025","article-title":"Arachidonic acid metabolism by human cardiovascular CYP2J2 is modulated by doxorubicin","volume":"56","author":"Arnold","year":"2017","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.122.001011_bib18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/157340708784533384","article-title":"The discovery and application of inhibitors of glutathione S-transferase as therapeutic agents-a review","volume":"4","author":"Ata","year":"2008","journal-title":"Curr Bioact Compd"},{"key":"10.1124\/dmd.122.001011_bib19","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Attard","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.001011_bib20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1124\/dmd.117.075929","article-title":"Stereospecific metabolism of R- and S-warfarin by human hepatic cytosolic reductases","volume":"45","author":"Barnette","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/dmd.121.000642","article-title":"Cytochrome P450 binding and bioactivation of tumor-targeted duocarmycin agents","volume":"50","author":"Bart","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib22","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2015.136440","article-title":"UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?","volume":"101","author":"Bhoi","year":"2016","journal-title":"Haematologica"},{"key":"10.1124\/dmd.122.001011_bib23","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bcp.2015.04.020","article-title":"Roles of human UDP-glucuronosyltransferases in clearance and homeostasis of endogenous substrates, and functional implications","volume":"96","author":"Bock","year":"2015","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib24","doi-asserted-by":"crossref","first-page":"9547","DOI":"10.1016\/S0021-9258(18)60566-6","article-title":"The aldo-keto reductase superfamily. cDNAs and deduced amino acid sequences of human aldehyde and aldose reductases","volume":"264","author":"Bohren","year":"1989","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib25","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.addr.2008.06.002","article-title":"Monoamine oxidase inactivation: from pathophysiology to therapeutics","volume":"60","author":"Bortolato","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1124\/dmd.122.001011_bib26","first-page":"239","article-title":"Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles","volume":"1","author":"Bradshaw","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.122.001011_bib27","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2174\/0929867043455530","article-title":"The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate","volume":"11","author":"Bradshaw","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1124\/dmd.122.001011_bib28","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12872-018-0757-9","article-title":"Xanthine oxidase inhibitors for prevention of cardiovascular events: a systematic review and meta-analysis of randomized controlled trials","volume":"18","author":"Bredemeier","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1124\/dmd.122.001011_bib29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0006-2952(99)00319-6","article-title":"High-affinity stereoselective reduction of the enantiomers of ketotifen and of ketonic nortriptyline metabolites by aldo-keto reductases from human liver","volume":"59","author":"Breyer-Pfaff","year":"2000","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib30","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1016\/j.bmc.2007.05.046","article-title":"Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development","volume":"15","author":"Bruno","year":"2007","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001011_bib31","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0163-7258(89)90122-8","article-title":"UDP-glucuronosyltransferases","volume":"43","author":"Burchell","year":"1989","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/nure.12024","article-title":"Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders","volume":"71","author":"Busbee","year":"2013","journal-title":"Nutr Rev"},{"key":"10.1124\/dmd.122.001011_bib33","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/jcb.24589","article-title":"Biomarkers of sensitivity to potent and selective antitumor 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F203) in ovarian cancer","volume":"114","author":"Callero","year":"2013","journal-title":"J Cell Biochem"},{"key":"10.1124\/dmd.122.001011_bib34","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-2275(20)32049-6","article-title":"Cytochrome P450 and arachidonic acid bioactivation. Molecular and functional properties of the arachidonate monooxygenase","volume":"41","author":"Capdevila","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1124\/dmd.122.001011_bib35","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1042\/CS20200310","article-title":"CYP1B1 as a therapeutic target in cardio-oncology","volume":"134","author":"Carrera","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"10.1124\/dmd.122.001011_bib36","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1016\/j.bmc.2007.11.035","article-title":"Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: structural analogues of PABA\/NO, an anti-cancer lead compound","volume":"16","author":"Chakrapani","year":"2008","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001011_bib37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/978-3-319-98788-0_13","article-title":"Aldo-keto reductases: mltifunctional proteins as therapeutic targets in diabetes and inflammatory disease","volume":"1032","author":"Chang","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/dmd.122.001011_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/jpet.109.152017","article-title":"Selective inhibitors of CYP2J2 related to terfenadine exhibit strong activity against human cancers in vitro and in vivo","volume":"329","author":"Chen","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001011_bib39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1124\/jpet.110.174805","article-title":"Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth","volume":"336","author":"Chen","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001011_bib40","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/0006-2952(94)90420-0","article-title":"Role of cellular glutathione and glutathione S-transferase in the expression of alkylating agent cytotoxicity in human breast cancer cells","volume":"47","author":"Chen","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib41","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.3390\/molecules24061156","article-title":"Purification and structural analysis of the effective anti-TMV compound \u03b5-poly-l-lysine produced by Streptomyces ahygroscopicus","volume":"24","author":"Chen","year":"2019","journal-title":"Molecules"},{"key":"10.1124\/dmd.122.001011_bib42","first-page":"291","article-title":"The roles of cytochrome P450 enzymes in prostate cancer development and treatment","volume":"32","author":"Chen","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.122.001011_bib43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/FJC.0b013e3181506445","article-title":"The soluble epoxide hydrolase as a pharmaceutical target for hypertension","volume":"50","author":"Chiamvimonvat","year":"2007","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib44","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/0006-2952(91)90468-K","article-title":"Enzymatic conjugation of chlorambucil with glutathione by human glutathione S-transferases and inhibition by ethacrynic acid","volume":"42","author":"Ciaccio","year":"1991","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib45","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical effects of xanthine oxidase inhibitors in hyperuricemic patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Med Princ Pract"},{"key":"10.1124\/dmd.122.001011_bib46","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1021\/acs.jmedchem.1c02150","article-title":"Discovery and in vivo proof of concept of a highly potent dual inhibitor of soluble epoxide hydrolase and acetylcholinesterase for the treatment of Alzheimer\u2019s disease","volume":"65","author":"Codony","year":"2022","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib47","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/biof.5520170112","article-title":"Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?","volume":"17","author":"Coles","year":"2003","journal-title":"Biofactors"},{"issue":"Pt A","key":"10.1124\/dmd.122.001011_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.cbi.2016.05.005","article-title":"Function and organization of the human cytosolic sulfotransferase (SULT) family","volume":"259","author":"Coughtrie","year":"2016","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.122.001011_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1074\/jbc.M201010200","article-title":"Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK","volume":"278","author":"Cuadrado","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib50","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/00008571-200110000-00006","article-title":"Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid","volume":"11","author":"Dai","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001011_bib51","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S0076-6879(05)00035-2","article-title":"Cancer and molecular biomarkers of phase 2","volume":"400","author":"Dalhoff","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.122.001011_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/00008571-200308000-00010","article-title":"UGT pharmacogenomics: implications for cancer risk and cancer therapeutics","volume":"13","author":"Desai","year":"2003","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001011_bib53","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1146\/annurev.pharmtox.43.100901.140251","article-title":"Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts","volume":"43","author":"Ding","year":"2003","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.122.001011_bib54","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nchembio.1429","article-title":"Integrated phenotypic and activity-based profiling links Ces3 to obesity and diabetes","volume":"10","author":"Dominguez","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1124\/dmd.122.001011_bib55","doi-asserted-by":"crossref","first-page":"30792","DOI":"10.1074\/jbc.M203642200","article-title":"Activation of the p38 signaling pathway by heat shock involves the dissociation of glutathione S-transferase Mu from Ask1","volume":"277","author":"Dorion","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib56","doi-asserted-by":"crossref","first-page":"8069","DOI":"10.1021\/bi4005705","article-title":"Mechanism of glutathione transferase P1-1-catalyzed activation of the prodrug canfosfamide (TLK286, TELCYTA)","volume":"52","author":"Dourado","year":"2013","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.122.001011_bib57","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-981-10-7757-9_5","article-title":"Monoamine oxidases","volume":"87","author":"Edmondson","year":"2018","journal-title":"Subcell Biochem"},{"key":"10.1124\/dmd.122.001011_bib58","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2174\/15680266113139990110","article-title":"CYP4 enzymes as potential drug targets: focus on enzyme multiplicity, inducers and inhibitors, and therapeutic modulation of 20-hydroxyeicosatetraenoic acid (20-HETE) synthase and fatty acid \u03c9-hydroxylase activities","volume":"13","author":"Edson","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.122.001011_bib59","doi-asserted-by":"crossref","first-page":"22243","DOI":"10.1074\/jbc.M301211200","article-title":"Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi","volume":"278","author":"Elsby","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/03602532.2016.1257021","article-title":"Microsomal cytochrome P450 as a target for drug discovery and repurposing","volume":"49","author":"El-Sherbeni","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.122.001011_bib61","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/0006-2952(92)90117-2","article-title":"Stereospecific reduction of haloperidol in human tissues","volume":"44","author":"Eyles","year":"1992","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib62","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/MNH.0000000000000088","article-title":"Cytochrome P450 eicosanoids in hypertension and renal disease","volume":"24","author":"Fan","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1124\/dmd.122.001011_bib63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1023\/B:BREA.0000041586.64371.88","article-title":"The experimental antitumor agents Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models","volume":"87","author":"Fichtner","year":"2004","journal-title":"Breast Cancer Res Treat"},{"key":"10.1124\/dmd.122.001011_bib64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00131746-200407000-00005","article-title":"The role of monoamine oxidase inhibitors in current psychiatric practice","volume":"10","author":"Fiedorowicz","year":"2004","journal-title":"J Psychiatr Pract"},{"key":"10.1124\/dmd.122.001011_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007687","article-title":"Intestinal UDP-glucuronosyltransferase as a potential target for the treatment and prevention of lymphatic filariasis","volume":"13","author":"Flynn","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1124\/dmd.122.001011_bib66","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.116.071753","article-title":"Cytochrome P450 and non-cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics","volume":"44","author":"Foti","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib67","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1021\/bi1020716","article-title":"Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function","volume":"50","author":"Foti","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.122.001011_bib68","series-title":"Encyclopedia of Drug Metabolism and Interactions","article-title":"Mechanisms of drug metabolism","author":"Foti","year":"2012"},{"key":"10.1124\/dmd.122.001011_bib69","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1124\/dmd.115.064576","article-title":"\u201cTarget-site\u201d drug metabolism and transport","volume":"43","author":"Foti","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib70","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2012.04.021","article-title":"CYP1B1 and hormone-induced cancer","volume":"324","author":"Gajjar","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.122.001011_bib71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/kfj061","article-title":"Human sulfotransferases and their role in chemical metabolism","volume":"90","author":"Gamage","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.122.001011_bib72","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1517\/17425255.2012.663352","article-title":"The role of aldehyde oxidase in drug metabolism","volume":"8","author":"Garattini","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.001011_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsbmb.2014.01.013","article-title":"A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone","volume":"143","author":"Garrido","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.122.001011_bib74","doi-asserted-by":"crossref","first-page":"8608","DOI":"10.1074\/jbc.M308613200","article-title":"Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase\/STAT pathways","volume":"279","author":"Gate","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib75","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1517\/14728222.5.4.477","article-title":"Glutathione S-transferases as emerging therapeutic targets","volume":"5","author":"Gat\u00e9","year":"2001","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/dmd.122.001011_bib76","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3390\/ijms22010013","article-title":"The multifaceted role of epoxide hydrolases in human health and disease","volume":"22","author":"Gautheron","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/dmd.122.001011_bib77","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.2174\/156802609789909812","article-title":"Chemical and biological explorations of the family of CC-1065 and the duocarmycin natural products","volume":"9","author":"Ghosh","year":"2009","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.122.001011_bib78","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.steroids.2014.12.021","article-title":"CYP17A1 inhibitors in castration-resistant prostate cancer","volume":"95","author":"Gomez","year":"2015","journal-title":"Steroids"},{"key":"10.1124\/dmd.122.001011_bib79","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1097\/FPC.0b013e3283559b22","article-title":"Metformin pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.122.001011_bib80","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/art.42000","article-title":"Clinical and preclinical evidence for roles of soluble epoxide hydrolase in osteoarthritis knee pain","volume":"74","author":"Gowler","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1124\/dmd.122.001011_bib81","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3109\/00498254.2011.597455","article-title":"Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222","volume":"41","author":"Greene","year":"2011","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.122.001011_bib82","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1158\/1078-0432.CCR-04-2111","article-title":"Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy","volume":"11","author":"Gribben","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib83","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-08-447359","article-title":"Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia","volume":"121","author":"Gruber","year":"2013","journal-title":"Blood"},{"key":"10.1124\/dmd.122.001011_bib84","series-title":"Cytochrome P450: Structure, Mechanism, and Biochemistry","first-page":"377","article-title":"Human cytochrome P450 enzymes","author":"Guengerich","year":"2005"},{"key":"10.1124\/dmd.122.001011_bib85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.chemrestox.6b00226","article-title":"Intersection of the roles of cytochrome P450 enzymes with xenobiotic and endogenous substrates: relevance to toxicity and drug interactions","volume":"30","author":"Guengerich","year":"2017","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001011_bib86","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10555-018-9749-6","article-title":"Targeting cytochrome P450-dependent cancer cell mitochondria: cancer associated CYPs and where to find them","volume":"37","author":"Guo","year":"2018","journal-title":"Cancer Metastasis Rev"},{"key":"10.1124\/dmd.122.001011_bib87","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/03602532.2018.1554674","article-title":"The engagement of brain cytochrome P450 in the metabolism of endogenous neuroactive substrates: a possible role in mental disorders","volume":"50","author":"Haduch","year":"2018","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.122.001011_bib88","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ctrv.2018.07.014","article-title":"Personalizing aromatase inhibitor therapy in patients with breast cancer","volume":"70","author":"Hamadeh","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1124\/dmd.122.001011_bib89","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","article-title":"Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative","volume":"64","author":"Hammock","year":"2021","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib90","first-page":"94","article-title":"Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid","volume":"51","author":"Hansson","year":"1991","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib91","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.gene.2013.05.008","article-title":"Soluble epoxide hydrolase: gene structure, expression and deletion","volume":"526","author":"Harris","year":"2013","journal-title":"Gene"},{"key":"10.1124\/dmd.122.001011_bib92","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14728222.2016.1226284","article-title":"Soluble epoxide hydrolase: a new therapeutic target for depression","volume":"20","author":"Hashimoto","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1124\/dmd.122.001011_bib93","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/hmg\/3.3.421","article-title":"Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants","volume":"3","author":"Hassett","year":"1994","journal-title":"Hum Mol Genet"},{"key":"10.1124\/dmd.122.001011_bib94","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1124\/dmd.108.023010","article-title":"Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans","volume":"37","author":"He","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib95","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/cmdc.202100326","article-title":"A fluorometric CYP19A1 (aromatase) activity assay in live cells","volume":"16","author":"Heidary","year":"2021","journal-title":"ChemMedChem"},{"key":"10.1124\/dmd.122.001011_bib96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cbi.2011.01.003","article-title":"Aldo-keto reductases AKR1C1, AKR1C2 and AKR1C3 may enhance progesterone metabolism in ovarian endometriosis","volume":"191","author":"Hevir","year":"2011","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.122.001011_bib97","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/jbt.20179","article-title":"Ontogeny of human hepatic cytochromes P450","volume":"21","author":"Hines","year":"2007","journal-title":"J Biochem Mol Toxicol"},{"key":"10.1124\/dmd.122.001011_bib98","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1093\/carcin\/bgq124","article-title":"Function of UDP-glucuronosyltransferase 2B17 (UGT2B17) is involved in endometrial cancer","volume":"31","author":"Hirata","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1124\/dmd.122.001011_bib99","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrd.2017.219","article-title":"Mechanistic enzymology in drug discovery: a fresh perspective","volume":"17","author":"Holdgate","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001011_bib100","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.3390\/cancers14225708","article-title":"The somatic mutation landscape of UDP-glycosyltransferase (UGT) genes in human cancers","volume":"14","author":"Hu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/dmd.122.001011_bib101","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib102","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib103","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bcp.2019.05.023","article-title":"A dual farnesoid X receptor\/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice","volume":"166","author":"Hye Khan","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2018.06.015","article-title":"Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics","volume":"192","author":"Imig","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib105","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/nrd2875","article-title":"Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases","volume":"8","author":"Imig","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001011_bib106","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1387-2656(01)07037-5","article-title":"Enzymatic studies on the key enzymes of vitamin D metabolism; 1 alpha-hydroxylase (CYP27B1) and 24-hydroxylase (CYP24)","volume":"7","author":"Inouye","year":"2001","journal-title":"Biotechnol Annu Rev"},{"key":"10.1124\/dmd.122.001011_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107400","article-title":"Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases","volume":"204","author":"Isoherranen","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib108","doi-asserted-by":"crossref","first-page":"103","DOI":"10.5507\/bp.2010.017","article-title":"Phase II drug metabolizing enzymes","volume":"154","author":"Jancova","year":"2010","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1124\/dmd.122.001011_bib109","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1042\/bj3260625","article-title":"Comparative anatomy of the aldo-keto reductase superfamily","volume":"326","author":"Jez","year":"1997","journal-title":"Biochem J"},{"key":"10.1124\/dmd.122.001011_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2022.116620","article-title":"High-throughput optical assays for sensing serine hydrolases in living systems and their applications","volume":"152","author":"Jin","year":"2022","journal-title":"Trends Analyt Chem"},{"key":"10.1124\/dmd.122.001011_bib111","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.apsb.2022.01.009","article-title":"Optical substrates for drug-metabolizing enzymes: recent advances and future perspectives","volume":"12","author":"Jin","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.122.001011_bib112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev.pharmtox.47.120505.105337","article-title":"Aldo-keto reductases and bioactivation\/detoxication","volume":"47","author":"Jin","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.122.001011_bib113","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.redox.2016.03.005","article-title":"Glutathione S-transferase pi modulates NF-\u03baB activation and pro-inflammatory responses in lung epithelial cells","volume":"8","author":"Jones","year":"2016","journal-title":"Redox Biol"},{"key":"10.1124\/dmd.122.001011_bib114","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.drudis.2020.11.020","article-title":"How can the potential of the duocarmycins be unlocked for cancer therapy?","volume":"26","author":"Jukes","year":"2021","journal-title":"Drug Discov Today"},{"issue":"Suppl 3","key":"10.1124\/dmd.122.001011_bib115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000119540","article-title":"Short review on monoamine oxidase and its inhibitors","volume":"34","author":"Kanazawa","year":"1994","journal-title":"Eur Neurol"},{"key":"10.1124\/dmd.122.001011_bib116","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.21873\/anticanres.15288","article-title":"Inhibition of CYP27B1 and CYP24 increases the anti-proliferative effects of 25-hydroxyvitamin D3 in LNCaP cells","volume":"41","author":"Karlsson","year":"2021","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.122.001011_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.202000081","article-title":"Aromatase inhibitors: role in postmenopausal breast cancer","volume":"353","author":"Kharb","year":"2020","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1124\/dmd.122.001011_bib118","doi-asserted-by":"crossref","first-page":"8890","DOI":"10.1111\/jcmm.15581","article-title":"Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential","volume":"24","author":"Khayami","year":"2020","journal-title":"J Cell Mol Med"},{"key":"10.1124\/dmd.122.001011_bib119","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2174\/1389200003339171","article-title":"UDP-glucuronosyltransferases","volume":"1","author":"King","year":"2000","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.122.001011_bib120","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/pharmaceutics12121201","article-title":"Drug-drug interactions involving intestinal and hepatic CYP1A enzymes","volume":"12","author":"Klomp","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.122.001011_bib121","doi-asserted-by":"crossref","first-page":"14076","DOI":"10.1021\/acsomega.8b01625","article-title":"Design and potency of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"3","author":"Kodani","year":"2018","journal-title":"ACS Omega"},{"key":"10.1124\/dmd.122.001011_bib122","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0003-9861(72)90078-1","article-title":"A comparison of the specificities of xanthine oxidase and aldehyde oxidase","volume":"150","author":"Krenitsky","year":"1972","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.122.001011_bib123","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000494496","article-title":"Glutathione S-transferases and cytochrome P450 enzyme expression in patients with intracranial tumors: preliminary report of 55 patients","volume":"28","author":"Kural","year":"2019","journal-title":"Med Princ Pract"},{"key":"10.1124\/dmd.122.001011_bib124","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/369156a0","article-title":"The stress-activated protein kinase subfamily of c-Jun kinases","volume":"369","author":"Kyriakis","year":"1994","journal-title":"Nature"},{"key":"10.1124\/dmd.122.001011_bib125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.pharmthera.2017.03.007","article-title":"Potential role of CYP1B1 in the development and treatment of metabolic diseases","volume":"178","author":"Li","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib126","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1600-0447.1990.tb05321.x","article-title":"Reversible and irreversible monoamine oxidase inhibitors in other psychiatric disorders","volume":"360","author":"Liebowitz","year":"1990","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1124\/dmd.122.001011_bib127","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1124\/dmd.117.075846","article-title":"Heme modification contributes to the mechanism-based inactivation of human cytochrome P450 2J2 by two terminal acetylenic compounds","volume":"45","author":"Lin","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib128","first-page":"967","article-title":"Cellular expression of xanthine oxidoreductase protein in normal human tissues","volume":"79","author":"Linder","year":"1999","journal-title":"Lab Invest"},{"key":"10.1124\/dmd.122.001011_bib129","doi-asserted-by":"crossref","first-page":"246","DOI":"10.2174\/157489209789206931","article-title":"Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives","volume":"4","author":"Liu","year":"2009","journal-title":"Recent Patents Anticancer Drug Discov"},{"key":"10.1124\/dmd.122.001011_bib130","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","article-title":"Overview of AKR1C3: inhibitor achievements and disease insights","volume":"63","author":"Liu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib131","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1021\/bi9706778","article-title":"Kinetic mechanism for p38 MAP kinase","volume":"36","author":"LoGrasso","year":"1997","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.122.001011_bib132","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.bcp.2013.08.011","article-title":"3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout","volume":"86","author":"L\u00fc","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib133","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1586\/14760584.7.7.995","article-title":"Targeting cytochrome P450 CYP1B1 with a therapeutic cancer vaccine","volume":"7","author":"Luby","year":"2008","journal-title":"Expert Rev Vaccines"},{"key":"10.1124\/dmd.122.001011_bib134","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/736837","article-title":"Glutathione homeostasis and functions: potential targets for medical interventions","volume":"2012","author":"Lushchak","year":"2012","journal-title":"J Amino Acids"},{"key":"10.1124\/dmd.122.001011_bib135","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2015.07.031","article-title":"Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSH-dependent mechanism","volume":"368","author":"Ma","year":"2015","journal-title":"Cancer Lett"},{"key":"10.1124\/dmd.122.001011_bib136","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2003-05-1374","article-title":"The shared tumor-associated antigen cytochrome P450 1B1 is recognized by specific cytotoxic T cells","volume":"102","author":"Maecker","year":"2003","journal-title":"Blood"},{"key":"10.1124\/dmd.122.001011_bib137","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jsbmb.2017.09.007","article-title":"CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2","volume":"174","author":"Malikova","year":"2017","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.122.001011_bib138","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/S0021-9258(18)63065-0","article-title":"On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo[3,4-d]pyrimidines","volume":"245","author":"Massey","year":"1970","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib139","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1517\/13543776.16.4.431","article-title":"Glutathione S-transferase (GST) inhibitors","volume":"16","author":"Mathew","year":"2006","journal-title":"Expert Opin Ther Pat"},{"key":"10.1124\/dmd.122.001011_bib140","doi-asserted-by":"crossref","first-page":"10737","DOI":"10.1039\/c1cc13872c","article-title":"Direct spectroscopic evidence for binding of anastrozole to the iron heme of human aromatase. Peering into the mechanism of aromatase inhibition","volume":"47","author":"Maurelli","year":"2011","journal-title":"Chem Commun (Camb)"},{"key":"10.1124\/dmd.122.001011_bib141","first-page":"263","article-title":"Basic review of the cytochrome p450 system","volume":"4","author":"McDonnell","year":"2013","journal-title":"J Adv Pract Oncol"},{"key":"10.1124\/dmd.122.001011_bib142","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1158\/1535-7163.363.3.3","article-title":"Cytochrome P450 enzymes: novel options for cancer therapeutics","volume":"3","author":"McFadyen","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.122.001011_bib143","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/14796694.1.2.259","article-title":"Cytochrome P450 1B1: a novel anticancer therapeutic target","volume":"1","author":"McFadyen","year":"2005","journal-title":"Future Oncol"},{"key":"10.1124\/dmd.122.001011_bib144","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2018.02.012","article-title":"Modulation of CYP1A1 metabolism: From adverse health effects to chemoprevention and therapeutic options","volume":"187","author":"Mescher","year":"2018","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib145","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ejmech.2016.05.063","article-title":"A novel class of ethacrynic acid derivatives as promising drug-like potent generation of anticancer agents with established mechanism of action","volume":"122","author":"Mignani","year":"2016","journal-title":"Eur J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib146","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/MJT.0b013e318195e460","article-title":"The clinical pharmacology of ethacrynic acid","volume":"16","author":"Molnar","year":"2009","journal-title":"Am J Ther"},{"key":"10.1124\/dmd.122.001011_bib147","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s002800050398","article-title":"Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines","volume":"37","author":"Morgan","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib148","doi-asserted-by":"crossref","first-page":"8849","DOI":"10.1073\/pnas.96.16.8849","article-title":"Potent urea and carbamate inhibitors of soluble epoxide hydrolases","volume":"96","author":"Morisseau","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.001011_bib149","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1124\/dmd.122.001011_bib150","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1210\/er.2015-1036","article-title":"The regulation of steroid action by sulfation and desulfation","volume":"36","author":"Mueller","year":"2015","journal-title":"Endocr Rev"},{"key":"10.1124\/dmd.122.001011_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121074","article-title":"Letrozole: pharmacology, toxicity and potential therapeutic effects","volume":"310","author":"Mukherjee","year":"2022","journal-title":"Life Sci"},{"key":"10.1124\/dmd.122.001011_bib152","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1359\/JBMR.041110","article-title":"Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density","volume":"20","author":"Napoli","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1124\/dmd.122.001011_bib153","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/03602532.2018.1439502","article-title":"Cytochrome P450 in the central nervous system as a therapeutic target in neurodegenerative diseases","volume":"50","author":"Navarro-Mabarak","year":"2018","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.122.001011_bib154","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/nrc2015","article-title":"The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis","volume":"6","author":"Nebert","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1124\/dmd.122.001011_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113912","article-title":"Hepatocellular carcinoma: gene expression profiling and regulation of xenobiotic-metabolizing cytochromes P450","volume":"177","author":"Nekvindova","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib156","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.2174\/1568026611313120004","article-title":"Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics","volume":"13","author":"Nelson","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.122.001011_bib157","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2004.10.001","article-title":"Epoxide hydrolases: their roles and interactions with lipid metabolism","volume":"44","author":"Newman","year":"2005","journal-title":"Prog Lipid Res"},{"key":"10.1124\/dmd.122.001011_bib158","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1016\/j.bmc.2006.02.041","article-title":"Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases","volume":"14","author":"Njar","year":"2006","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001011_bib159","first-page":"6059","article-title":"Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid","volume":"51","author":"O\u2019Dwyer","year":"1991","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib160","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1074\/jbc.M208307200","article-title":"An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition","volume":"278","author":"Okamoto","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib161","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/annonc\/mdv487","article-title":"Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer","volume":"27","author":"O\u2019Shaughnessy","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1124\/dmd.122.001011_bib162","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1111\/cas.13309","article-title":"Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer","volume":"108","author":"Otsubo","year":"2017","journal-title":"Cancer Sci"},{"key":"10.1124\/dmd.122.001011_bib163","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nrd2199","article-title":"How many drug targets are there?","volume":"5","author":"Overington","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001011_bib164","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1124\/pr.58.1.6","article-title":"Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.122.001011_bib165","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \u201cpie\u201d","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib166","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1021\/tx030059u","article-title":"Contribution of aldehyde oxidase, xanthine oxidase, and aldehyde dehydrogenase on the oxidation of aromatic aldehydes","volume":"17","author":"Panoutsopoulos","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.122.001011_bib167","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0006-8993(99)01381-5","article-title":"Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites","volume":"830","author":"Park-Chung","year":"1999","journal-title":"Brain Res"},{"key":"10.1124\/dmd.122.001011_bib168","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cbi.2014.09.024","article-title":"The aldo-keto reductases (AKRs): overview","volume":"234","author":"Penning","year":"2015","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.122.001011_bib169","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1749-6632.2009.03700.x","article-title":"Steroid hormone transforming aldo-keto reductases and cancer","volume":"1155","author":"Penning","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1124\/dmd.122.001011_bib170","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.abb.2007.04.024","article-title":"Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms","volume":"464","author":"Penning","year":"2007","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.122.001011_bib171","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1124\/pharmrev.120.000122","article-title":"Aldo-keto reductases and cancer drug resistance","volume":"73","author":"Penning","year":"2021","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.122.001011_bib172","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1210\/er.2018-00089","article-title":"Structural and functional biology of aldo-keto reductase steroid-transforming enzymes","volume":"40","author":"Penning","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1124\/dmd.122.001011_bib173","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00018-003-3402-3","article-title":"All in the family: aldose reductase and closely related aldo-keto reductases","volume":"61","author":"Petrash","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1124\/dmd.122.001011_bib174","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.1993.tb03187.x","article-title":"Reversing of chlorambucil resistance by ethacrynic acid in a B-CLL patient","volume":"85","author":"Petrini","year":"1993","journal-title":"Br J Haematol"},{"key":"10.1124\/dmd.122.001011_bib175","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.pharmthera.2006.05.014","article-title":"Cytochrome P450s and cholesterol homeostasis","volume":"112","author":"Pikuleva","year":"2006","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib176","doi-asserted-by":"crossref","first-page":"17091","DOI":"10.1074\/jbc.R112.431916","article-title":"Cytochromes P450: roles in diseases","volume":"288","author":"Pikuleva","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib177","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1016\/0006-2952(90)90465-W","article-title":"Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate","volume":"40","author":"Ploemen","year":"1990","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib178","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jsbmb.2010.03.065","article-title":"Vitamin D analogues targeting CYP24 in chronic kidney disease","volume":"121","author":"Posner","year":"2010","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.122.001011_bib179","doi-asserted-by":"crossref","first-page":"18930","DOI":"10.1038\/s41598-021-98217-z","article-title":"Cytochrome P450 isoforms 1A1, 1B1 AND 2W1 as targets for therapeutic intervention in head and neck cancer","volume":"11","author":"Presa","year":"2021","journal-title":"Sci Rep"},{"key":"10.1124\/dmd.122.001011_bib180","doi-asserted-by":"crossref","first-page":"8441","DOI":"10.1021\/jm100888d","article-title":"Aldehyde oxidase: an enzyme of emerging importance in drug discovery","volume":"53","author":"Pryde","year":"2010","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib181","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1081\/DMR-100101944","article-title":"Structural and functional studies of UDP-glucuronosyltransferases","volume":"31","author":"Radominska-Pandya","year":"1999","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.122.001011_bib182","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2174\/1871520620666200627204105","article-title":"Aromatase inhibitors for the treatment of breast cancer: a journey from the scratch","volume":"20","author":"Ratre","year":"2020","journal-title":"Anticancer Agents Med Chem"},{"key":"10.1124\/dmd.122.001011_bib183","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1359-6446(05)03383-0","article-title":"Mammalian carboxylesterases: from drug targets to protein therapeutics","volume":"10","author":"Redinbo","year":"2005","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.122.001011_bib184","doi-asserted-by":"crossref","first-page":"E1944","DOI":"10.1073\/pnas.1601532113","article-title":"Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress","volume":"113","author":"Ren","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.001011_bib185","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1158\/1541-7786.MCR-12-0675","article-title":"CYP1A1 regulates breast cancer proliferation and survival","volume":"11","author":"Rodriguez","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib186","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00394-011-0269-1","article-title":"Procyanidin B2 induces Nrf2 translocation and glutathione S-transferase P1 expression via ERKs and p38-MAPK pathways and protect human colonic cells against oxidative stress","volume":"51","author":"Rodr\u00edguez-Ramiro","year":"2012","journal-title":"Eur J Nutr"},{"key":"10.1124\/dmd.122.001011_bib187","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1517\/17425255.2014.859675","article-title":"Cytochrome P450 and ischemic heart disease: current concepts and future directions","volume":"10","author":"Rowland","year":"2014","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.001011_bib188","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","article-title":"The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification","volume":"45","author":"Rowland","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1124\/dmd.122.001011_bib189","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fphar.2012.00058","article-title":"Biological role of aldo-keto reductases in retinoic acid biosynthesis and signaling","volume":"3","author":"Ruiz","year":"2012","journal-title":"Front Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib190","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0022-3565(24)29386-1","article-title":"Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways","volume":"298","author":"Ruscoe","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001011_bib191","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/pharmaceutics5020220","article-title":"Glutathione transferase (GST)-activated prodrugs","volume":"5","author":"Ruzza","year":"2013","journal-title":"Pharmaceutics"},{"key":"10.1124\/dmd.122.001011_bib192","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1021\/jm050700k","article-title":"PABA\/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity","volume":"49","author":"Saavedra","year":"2006","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib193","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1124\/dmd.115.068593","article-title":"Hepatic cytochrome P450 activity, abundance, and expression throughout human development","volume":"44","author":"Sadler","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib194","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/dmd.122.001011_bib195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cmdc.201900576","article-title":"Dual farnesoid X receptor\/soluble epoxide hydrolase modulators derived from zafirlukast","volume":"15","author":"Schierle","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1124\/dmd.122.001011_bib196","doi-asserted-by":"crossref","first-page":"9772","DOI":"10.1073\/pnas.0503279102","article-title":"Soluble epoxide hydrolase is a therapeutic target for acute inflammation","volume":"102","author":"Schmelzer","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.001011_bib197","doi-asserted-by":"crossref","first-page":"7703","DOI":"10.1021\/acs.jmedchem.7b00398","article-title":"A dual modulator of farnesoid X receptor and soluble epoxide hydrolase to counter nonalcoholic steatohepatitis","volume":"60","author":"Schmidt","year":"2017","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib198","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1083\/jcb.32.3.719","article-title":"The submitochondrial localization of monoamine oxidase. An enzymatic marker for the outer membrane of rat liver mitochondria","volume":"32","author":"Schnaitman","year":"1967","journal-title":"J Cell Biol"},{"key":"10.1124\/dmd.122.001011_bib199","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0039-128X(00)00159-8","article-title":"Selective inhibition of vitamin D hydroxylases in human keratinocytes","volume":"66","author":"Schuster","year":"2001","journal-title":"Steroids"},{"issue":"4A","key":"10.1124\/dmd.122.001011_bib200","first-page":"2653","article-title":"Selective inhibitors of vitamin D metabolism--new concepts and perspectives","volume":"26","author":"Schuster","year":"2006","journal-title":"Anticancer Res"},{"key":"10.1124\/dmd.122.001011_bib201","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.2174\/1381612023394539","article-title":"Duocarmycins--natures prodrugs?","volume":"8","author":"Searcey","year":"2002","journal-title":"Curr Pharm Des"},{"key":"10.1124\/dmd.122.001011_bib202","first-page":"251","article-title":"Microsomal epoxide hydrolase. Properties, regulation and function","volume":"695","author":"Seideg\u00e5rd","year":"1983","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.122.001011_bib203","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0965-1748(02)00115-7","article-title":"Urea and amide-based inhibitors of the juvenile hormone epoxide hydrolase of the tobacco hornworm (Manduca sexta: Sphingidae)","volume":"32","author":"Severson","year":"2002","journal-title":"Insect Biochem Mol Biol"},{"key":"10.1124\/dmd.122.001011_bib204","first-page":"409","article-title":"JS-K, a glutathione\/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity","volume":"2","author":"Shami","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/dmd.122.001011_bib205","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1021\/jm201468j","article-title":"Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications","volume":"55","author":"Shen","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.122.001011_bib206","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jsbmb.2019.01.005","article-title":"Mammary-specific ablation of Cyp24a1 inhibits development, reduces proliferation and increases sensitivity to vitamin D","volume":"189","author":"Sheng","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.122.001011_bib207","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.clinthera.2015.07.022","article-title":"Cobicistat: review of a pharmacokinetic enhancer for HIV infection","volume":"37","author":"Sherman","year":"2015","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.122.001011_bib208","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s41021-017-0076-x","article-title":"Modulation of benzo[a]pyrene-DNA adduct formation by CYP1 inducer and inhibitor","volume":"39","author":"Shiizaki","year":"2017","journal-title":"Genes Environ"},{"key":"10.1124\/dmd.122.001011_bib209","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.114.056994","article-title":"Screening of specific inhibitors for human carboxylesterases or arylacetamide deacetylase","volume":"42","author":"Shimizu","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.122.001011_bib210","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1007\/s10120-017-0720-y","article-title":"Phase 1 study of sulfasalazine and cisplatin for patients with CD44v-positive gastric cancer refractory to cisplatin (EPOC1407)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1124\/dmd.122.001011_bib211","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10120-016-0610-8","article-title":"Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205)","volume":"20","author":"Shitara","year":"2017","journal-title":"Gastric Cancer"},{"key":"10.1124\/dmd.122.001011_bib212","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1073\/pnas.1613246113","article-title":"Targeting CYP2J to reduce paclitaxel-induced peripheral neuropathic pain","volume":"113","author":"Sisignano","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.122.001011_bib213","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.drudis.2020.07.002","article-title":"Exploring CYP2J2: lipid mediators, inhibitors and therapeutic implications","volume":"25","author":"Sisignano","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1124\/dmd.122.001011_bib214","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.122.001011_bib215","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/cncr.10844","article-title":"Selective aromatase inhibition for patients with androgen-independent prostate carcinoma","volume":"95","author":"Smith","year":"2002","journal-title":"Cancer"},{"key":"10.1124\/dmd.122.001011_bib216","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/biomedicines9030290","article-title":"Intratumoural cytochrome P450 expression in breast cancer: impact on standard of care treatment and new efforts to develop tumour-selective therapies","volume":"9","author":"Sneha","year":"2021","journal-title":"Biomedicines"},{"key":"10.1124\/dmd.122.001011_bib217","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/1568026621666210701143445","article-title":"Relevance of aromatase inhibitors in breast cancer treatment","volume":"21","author":"Sood","year":"2021","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/dmd.122.001011_bib218","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bbalip.2014.07.020","article-title":"Cytochrome P450 epoxygenase pathway of polyunsaturated fatty acid metabolism","volume":"1851","author":"Spector","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/dmd.122.001011_bib219","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/0006-2952(77)90191-5","article-title":"Inhibition of urate production by allopurinol","volume":"26","author":"Spector","year":"1977","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1042\/BJ20061743","article-title":"Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes","volume":"405","author":"Spite","year":"2007","journal-title":"Biochem J"},{"key":"10.1124\/dmd.122.001011_bib221","article-title":"Dual soluble epoxide hydrolase inhibitor\/PPAR-\u03b3 agonist attenuates renal fibrosis","volume":"150","author":"Stavniichuk","year":"2020","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1124\/dmd.122.001011_bib222","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/bs.apha.2015.04.006","article-title":"Role of retinoic acid-metabolizing cytochrome P450s, CYP26, in inflammation and cancer","volume":"74","author":"Stevison","year":"2015","journal-title":"Adv Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib223","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/0165-6147(90)90008-V","article-title":"UDP-glucuronosyltransferases: a family of detoxifying enzymes","volume":"11","author":"Tephly","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.122.001011_bib224","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1517\/13543784.14.8.1047","article-title":"TLK-286: a novel glutathione S-transferase-activated prodrug","volume":"14","author":"Tew","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/dmd.122.001011_bib225","first-page":"3622","article-title":"Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines","volume":"48","author":"Tew","year":"1988","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib226","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1054\/drup.1999.0086","article-title":"GST function in drug and stress response","volume":"2","author":"Tew","year":"1999","journal-title":"Drug Resist Updat"},{"key":"10.1124\/dmd.122.001011_bib227","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40170-021-00249-6","article-title":"Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models","volume":"9","author":"Thanee","year":"2021","journal-title":"Cancer Metab"},{"key":"10.1124\/dmd.122.001011_bib228","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/17425250903032681","article-title":"The role of CYP26 enzymes in retinoic acid clearance","volume":"5","author":"Thatcher","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.122.001011_bib229","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1211\/jpp.61.05.0002","article-title":"Cytochrome P450-mediated metabolism in the human gut wall","volume":"61","author":"Thelen","year":"2009","journal-title":"J Pharm Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/35.1.3025289","article-title":"Immunocytochemical localization of monoamine oxidases A and B in human peripheral tissues and brain","volume":"35","author":"Thorpe","year":"1987","journal-title":"J Histochem Cytochem"},{"key":"10.1124\/dmd.122.001011_bib231","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0076-6879(05)01019-0","article-title":"Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets","volume":"401","author":"Townsend","year":"2005","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.122.001011_bib232","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"10.1124\/dmd.122.001011_bib233","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1200\/JCO.1989.7.8.1093","article-title":"High-dose ketoconazole in advanced hormone-refractory prostate cancer: endocrinologic and clinical effects","volume":"7","author":"Trump","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1124\/dmd.122.001011_bib234","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1177\/1060028017717018","article-title":"Cobicistat versus ritonavir: similar pharmacokinetic enhancers but some important differences","volume":"51","author":"Tseng","year":"2017","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.122.001011_bib235","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1021\/acs.molpharmaceut.6b00140","article-title":"Chemical reactivity window determines prodrug efficiency toward glutathione transferase overexpressing cancer cells","volume":"13","author":"van Gisbergen","year":"2016","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.122.001011_bib236","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2174\/1874467214666210920104352","article-title":"A clinical perspective of soluble epoxide hydrolase inhibitors in metabolic and related cardiovascular diseases","volume":"15","author":"Verma","year":"2022","journal-title":"Curr Mol Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib237","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1161\/01.RES.0000187474.47805.30","article-title":"Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium","volume":"97","author":"Vriens","year":"2005","journal-title":"Circ Res"},{"key":"10.1124\/dmd.122.001011_bib238","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.122.001011_bib239","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","article-title":"Human carboxylesterases: a comprehensive review","volume":"8","author":"Wang","year":"2018","journal-title":"Acta Pharm Sin B"},{"key":"10.1124\/dmd.122.001011_bib240","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0022-3565(24)37347-1","article-title":"Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors","volume":"284","author":"Wang","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.122.001011_bib241","doi-asserted-by":"crossref","first-page":"20999","DOI":"10.1074\/jbc.M101355200","article-title":"Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus","volume":"276","author":"Wang","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.122.001011_bib242","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00008571-200002000-00004","article-title":"Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer","volume":"10","author":"Watanabe","year":"2000","journal-title":"Pharmacogenetics"},{"key":"10.1124\/dmd.122.001011_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116507","article-title":"Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"51","author":"Wilt","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1124\/dmd.122.001011_bib244","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10408449209145319","article-title":"The human hepatic cytochromes P450 involved in drug metabolism","volume":"22","author":"Wrighton","year":"1992","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.122.001011_bib245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tox.2007.05.021","article-title":"Aldo-keto reductases (AKR) from the AKR1C subfamily catalyze the carbonyl reduction of the novel anticancer drug oracin in man","volume":"238","author":"Wsol","year":"2007","journal-title":"Toxicology"},{"key":"10.1124\/dmd.122.001011_bib246","first-page":"4053","article-title":"Glutathione S-transferase p elicits protection against H2O2-induced cell death via coordinated regulation of stress kinases","volume":"60","author":"Yin","year":"2000","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.122.001011_bib247","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00702-004-0143-x","article-title":"Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson\u2019s disease and other neurodegenerative diseases","volume":"111","author":"Youdim","year":"2004","journal-title":"J Neural Transm (Vienna)"},{"issue":"7 Suppl 2","key":"10.1124\/dmd.122.001011_bib248","first-page":"S32","article-title":"A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson\u2019s disease","volume":"63","author":"Youdim","year":"2004","journal-title":"Neurology"},{"key":"10.1124\/dmd.122.001011_bib249","doi-asserted-by":"crossref","first-page":"5641","DOI":"10.3390\/cancers14225641","article-title":"CYP1B1: a novel molecular biomarker predicts molecular subtype, tumor microenvironment, and immune response in 33 cancers","volume":"14","author":"Yuan","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1124\/dmd.122.001011_bib250","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dkh029","article-title":"Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients","volume":"53","author":"Zeldin","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1124\/dmd.122.001011_bib251","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/164_2020_392","article-title":"Development of Telintra as an inhibitor of glutathione S-transferase P","volume":"264","author":"Zhang","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/dmd.122.001011_bib252","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting strategies for tissue-specific drug delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1124\/dmd.122.001011_bib253","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00004714-199312000-00005","article-title":"Treatment of depression in bipolar disorder: new directions for research","volume":"13","author":"Zornberg","year":"1993","journal-title":"J Clin Psychopharmacol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.122.001011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:04:36Z","timestamp":1739937876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":253,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0090955624010201"],"URL":"https:\/\/doi.org\/10.1124\/dmd.122.001011","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytochrome P450 and Other Drug-Metabolizing Enzymes As Therapeutic Targets","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.122.001011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}